ADA TV

ADA TV is in Orlando, Florida June 2018.

In its 3rd year, ADA TV is in Orlando, Florida at the 2018 ADA Annual Meeting, with more than 13,000 attendees expected. ADA's Scientific Session is the world's largest meeting on Diabetes helping to discover cutting-edge research and new advances in diabetes care.

The channel serves to raise the visibility of best practices in the field, as well as to highlight collaborations between diverse institutions including university departments, research institutions and private sector organizations.

ADA TV launched in partnership with The American Diabetes Association (ADA) at ADA's annual meeting in 2015.

Along with highlights from the meeting and interviews with key speakers, we produced films for organizations working in the field of diabetes highlighting the great work that is being done in the USA and around the world.

Where to Watch ADA TV

Twitter: @WebsEdge_Health
Facebook: @WebsEdgeHealth
YouTube: https://www.youtube.com/WebsEdgeHealth
WebsEdge: http://www.websedge.com/videos/ada_tv_2018/

Follow along with ADA 2018 on twitter:
#2018ADA @ada_diabetespro @WebsEdge_Health

ADA TV Highlights

PreventAGE HEALTH CARE, LLC
KNOW YOUR RISK, CHANGE YOUR OUTCOME

Based on the most sophisticated and comprehensive longitudinal diabetes studies ever completed, PreventAGE Health Care has developed cutting edge, precision bioanalytical technologies and algorithms to assess the risk of patient progression to complications. With a routine blood sample, patients can know their likelihood of developing the two most serious and ravaging diabetic complications: kidney disease and cardiovascular disease.
PreventAGE Health Care

ASCENSIA Diabetes Care

Established in 2016 through the acquisition of Bayer Diabetes Care by Panasonic Healthcare Holdings, Ascensia Diabetes Care is a global company dedicated to improving the health and lives of people with diabetes. Ascensia diabetes management solutions continue to evolve with new capabilities, providing innovative tools for patients with diabetes now and in the future. Already including the world–renowned CONTOUR™ range of blood glucose monitoring systems, Ascensia is committed to adding more innovative and life changing products to their portfolio.
Ascensia Diabetes Care

Boehringer Ingelheim

Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.

Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects such as the "Making More Health" initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees' different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
Boehringer Ingelheim

UNIVERSITY OF CAMBRIDGE
Department of Paediatrics

The University of Cambridge's Department of Paediatrics is focused on doing potentially life-changing translational research involving young people with type 1 diabetes. With a combination of cutting edge facilities, dynamic collaborations in the UK and beyond as well as connections to a wide network of patients, Cambridge's Department of Paediatrics is at the forefront of new research into type 1 diabetes in young people.
Department of Paediatrics, University of Cambridge

DIABETES UK
KNOW DIABETES. FIGHT DIABETES.

Diabetes UK has an 80-year legacy in funding research and have been behind some of the greatest breakthroughs in diabetes care. With an ever-changing diabetes landscape, Diabetes UK continues to look forward into the future to have the most impact on the lives of people with diabetes.

To this end, Diabetes UK has established the diabetes Clinical Studies Groups. These groups of academic researchers, healthcare professionals and people with diabetes are tasked with scanning the horizon across clinical research and identifying areas of unmet clinical need. Their work will help focus research investment on the areas of greatest potential impact for people with diabetes.
Diabetes UK

Ochsner
Frank Riddick Diabetes Institute

The Frank Riddick Diabetes Institute at Ochsner Health System is dedicated to serving people with or at risk for diabetes and those who care about them by providing state of the art healing care. The Institute also provides innovative education programs and conducts research contributing to the development of new diabetes treatments and health care delivery systems.
Frank Riddick Diabetes Institute at Ochsner Health System

Gan & Lee

China is seeing a rapid increase in diabetes prevalence, with numbers close to those in the USA and other high-prevalence western countries. At the same time, studies suggest high numbers at the pre-diabetes stage, indicating numbers are set to increase further. To meet these challenges requires a comprehensive approach in health systems across China. With the support of the government, China Diabetes Society and other leading diabetes organizations in China, diabetes experts and endocrinology departments across the country are leading the way in establishing shared care teams to ensure every diabetes patient receives comprehensive education as to how to manage their disease.
Gan & Lee Pharmaceuticals

Gan & Lee

Research into Biosimilars is leading to a potential paradigm shift in the way diabetes is treated around the world. This kind of research is increasingly urgent in China, where the population is seeing rapid increases in the prevalence of diabetes, coming close to 1 in 10 adults. In China, where the cost of insulin products is often prohibitive for many people in the country, leading Chinese pharmaceutical companies like Gan & Lee are working to bring new products to the market to meet the needs of Chinese increasing population of people living with diabetes.
Gan & Lee Pharmaceuticals

Gan & Lee Pharmaceuticals is a high-tech biopharmaceutical company specialized in research, development, production and commercialization of insulin and its analogues, leading in the diabetes market in China. Since they began in 1998 Gan & Lee has focused on research and development into insulin production, providing life-changing products to those living with diabetes in China and around the world. Gan & Lee are now working on bringing their products to the US market, where the cost of insulin has increased dramatically. Through partnerships with US experts in the industry, Gan & Lee should be able to make a major difference to patients' lives in the USA.

Gan & Lee Pharmaceuticals

In recent years, China has become a major battlefield in the fight against Diabetes with over 120 million patients. At the same time, research suggests a difference in disease aetiology between China and western countries, as well as a population that has a different set of medical needs. This calls for a new approach as well as novel drugs in combating the disease. Hua Medicine has brought together global resources as well as the nation's best researchers and investigators to search for a cure for diabetes. With in-depth knowledge of glucokinase and its role in glucose homeostasis, Hua Medicine has created an "A Team" in China to take this expertise from bench to bed side.

Hua Medicine

In response to the diabetes epidemic among American Indian and Alaska Native (AI/AN) people, Congress established the Special Diabetes Program for Indians (SDPI) in 1997 to provide funds for diabetes prevention and treatment services. This $150 million annual grant program, coordinated by the Indian Health Service (IHS), allows AI/AN communities to provide much needed diabetes prevention programs and increase access to quality diabetes care. This collaboration between IHS and over 300 tribal, IHS, and urban programs across 35 states has helped make possible a remarkable 54% reduction in end-stage renal disease incidence and has similarly cut the incidence of diabetic eye disease by at least half in AI/AN people. The Chickasaw Nation Diabetes Program in Oklahoma is one such program that has utilized SDPI resources to build a successful integrated care model which incorporates a focus on social determinants of health to improve health outcomes and create a healthier community. Through a commitment to provide excellent diabetes care and prevention services, and honoring diverse cultural perspectives, IHS and SDPI grantees are changing the course of diabetes for AI/AN people.

Indian Health Service

Ironwood is evaluating products in the diabetes and cardiovascular spaces, with a promising product candidate being investigated in Phase II clinical studies as a potential treatment for diabetic nephropathy, a significant complication of diabetes, as well as a potential treatment for heart failure with preserved ejection fraction.

Ironwood Pharmaceuticals

Based on 50 years of clinical research, Dr. Mayer Davidson and Mellitus Health, Inc. have developed a proprietary, algorithm-based solution that helps clinicians tailor insulin dosing in ways that significantly lower HbA1C levels within a few months in most patients, even those with hard-to-manage diabetes. Early studies suggest that this is a significant advance in the care of people with diabetes, including those with the greatest risk of developing dangerous complications.

Mellitus Health, Inc.

Diabetic retinopathy is a sight threatening microvascular diabetic complication. Recently it became clear that it is not hyperglycemia alone, but rather the combination of hyperglycemia and dyslipidemia that lead to the development of DR, which is the focus of our research.

Michigan State University & University of Alabama at Birmingham

Mount Sinai Health System scientists are on the frontlines of advancing care and identifying cures for chronic illnesses related to Diabetes, Insulin Resistance, Women's Health, Cancer and Obesity. In this film, we look at the accomplishments being made in Beta Cell Regeneration and the work being done to find cures for people who live with Cancer, Polycystic Ovary Syndrome (PCOS) and Diabetes.

Mount Sinai Health System

With support from the Australian Research Council and JDRF Australia, researchers at the University of Sydney have identified a set of microRNAs that can potentially assess the death of insulin-producing beta-cells in individuals with or progressing to Type 1 diabetes, monitor islet graft health, and assess efficacies of drugs aimed to retard beta-cell death. In collaboration with the RMIT University, they describe the development of point-of-care devices for Type 1 diabetes.

NHMRC Clinical Trials Centre, University of Sydney

Managing day-to-day blood sugar levels during pregnancy is very challenging for women with type 1 diabetes. Nonetheless even small improvements in day-today glucose control can have a large impact on new born health outcomes. Mothers who spend an extra 100 minutes per day in the recommended target glucose range have babies who are less likely to be overweight, less likely to require neonatal intensive care unit admission and less likely to be born with low glucose levels.

Norwich Medical School, University of East Anglia

Non-alcoholic steatohepatitis (NASH) is a serious, progressive form of non-alcoholic fatty liver disease (NAFLD). NASH is expected to be the leading cause of liver transplants within the next decade. Pfizer researchers are working to develop treatments for NASH and its complications to fill the existing significant unmet medical need.

Pfizer

Generating a better understanding of how our medicines work in the real world ultimately allows us to benefit the patients that we serve. As a pioneer in real-world evidence (RWE) in diabetes, Sanofi has been building a large set of real world data for its insulins. Data of this kind helps demonstrate the value that our medicines bring to physicians and patients. Importantly, our RWE program helps evaluate the true effect of basal insulins on severe hypoglycemia. Sanofi has taken an innovative approach to generating this type of evidence, with the use of advanced statistical techniques and big data.

Sanofi

Steno Diabetes Center North Jutland was a reality the 1st of January 2018 and is one of five Steno Diabetes Centers in Denmark which is the result of a public-private partnership and grant between the Novo Nordisk Foundation and the public health care system in Denmark.

Steno Diabetes Center North Jutland, Denmark

University of North Carolina at Chapel Hill's School of Medicine has taken an interdisciplinary approach to tackling diabetes. From the development of drug delivery systems such as the "smart insulin" patch to leading worldwide clinical trials, UNC is making itself known around the world as a top-tier research institution. This research strength coupled with its strong emphasis in collaboration enables UNC to make life-changing discoveries for people living with diabetes.

University of North Carolina at Chapel Hill

Over the past half century the incidence of obesity and type 2 diabetes has gone from non-existent in most parts of the world to greater than 50% of the population. Research from VeroScience's laboratory and from many others point to important roles for the biological clock systems of the body that evolved to regulate metabolism in anticipation of ensuing seasons of food scarcity or abundance. Such clock mechanisms are responsible for the actual SEASONAL induction of the obese insulin resistant state (for survival against low glucose supply for the brain during seasons when none is naturally available in the wild) as well as for its reversal at appropriate seasons of the year when food is scarce and abundant, respectively. The clock mechanism also responds to westernized lifestyle "stress" signals from high fat diet, altered sleep wake cycles, social stress, and altered photoperiods to move the animal into the "survival mode" of the obese insulin resistant state. VersoScience's work over the past several decades has revealed methods of such resetting.

VeroScience

The south Asian region has some of the highest rates of diabetes in the world. Based in India, Wellthy Therapeutics is a leading digital therapeutics company providing comprehensive lifestyle and nutritional support for management of Type 2 diabetes. Their digital therapeutic connects patients with Wellthy's team of expert health coaches, providing them with customised advice and support to manage their disease. This is the only prescribable app for health management in diabetes in India, and is supported by a number of clinical advisors – expert diabetologists who see the effect the system has had on their patients.

Wellthy Therapeutics